[{"id":"a49319c7-fc86-477e-9d18-340184f8a72b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193853","created_at":"2021-01-18T15:44:59.657Z","updated_at":"2025-02-25T14:50:33.000Z","phase":"Phase 2","brief_title":"TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03193853","lead_sponsor":"Joyce O'Shaughnessy","biomarkers":" AR","pipe":" | ","alterations":" AR negative","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • albumin-bound paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-08-07"}]